Use of interrupter technique in assessment of bronchial responsiveness in normal subjects by Panagou, Panagiotis et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Pulmonary Medicine
Open Access Research article
Use of interrupter technique in assessment of bronchial 
responsiveness in normal subjects
Panagiotis Panagou1, Ioannis Kottakis2, Argyris Tzouvelekis2, 
Stavros Anevlavis2 and Demosthenes Bouros*2
Address: 1Department of Pneumonology, Army General Hospital, Athens, Greece and 2Department of Pneumonology, Medical School, University 
of Thrace, Alexandroupolis, Greece
Email: Panagiotis Panagou - pbpanagou@yahoo.gr; Ioannis Kottakis - i.kottakis@chiesigroup.com; 
Argyris Tzouvelekis - atzouvelekis@yahoo.gr; Stavros Anevlavis - anevlavis@yahoo.com; Demosthenes Bouros* - bouros@med.duth.gr
* Corresponding author    
Abstract
Background: A number of subjects, especially the very young and the elderly, are unable to
cooperate and to perform forced expiratory manoeuvres in the evaluation of bronchial
hyperresponsiveness (BHR). The objective of our study was to investigate the use of the
interrupter technique as a method to measure the response to provocation and to compare it with
the conventional PD20 FEV1.
Methods: We studied 170 normal subjects, 100 male and 70 female (mean ± SD age, 38 ± 8.5 and
35 ± 7.5 years, respectively), non-smoking from healthy families. These subjects had no respiratory
symptoms, rhinitis or atopic history. A dosimetric cumulative inhalation of methacholine was used
and the response was measured by the dose which increases baseline end interruption resistance
by 100% (PD100Rint, EI) as well as by percent dose response ratio (DRR).
Results:  BHR at a cut-off level of 0.8 mg methacholine exhibited 31 (18%) of the subjects
(specificity 81.2%), 21 male and 10 female, while 3% showed a response in the asthmatic range. The
method was reproducible and showed good correlation with PD20FEV1 (r = 0.76, p < 0.005), with
relatively narrow limits of agreement at -1.39 µmol and 1.27 µmol methacholine, respectively, but
the interrupter methodology proved more sensitive than FEV1 in terms of reactivity (DRR).
Conclusions: Interrupter methodology is clinically useful and may be used to evaluate bronchial
responsiveness in normal subjects and in situations when forced expirations cannot be performed.
Background
It is known that assessment of bronchial responsiveness
incorporating measurements of forced expiration can be
problematic because of limited co-operation and fatigue
and dizziness due to repeated forced expiratory manoeu-
vres. In addition, a deep inspiration, as it is required dur-
ing an FEV1  (Forced Expiratory Volume in 1 sec)
procedure, causes transient bronchodilatation particularly
in normals during challenge with pharmaceutical sub-
stances, resulting in interpretation difficulties [1]. Deter-
mining bronchial reactivity using a technique which
measures airways resistance is less influenced by inspira-
tory and expiratory efforts. Furthermore, it is more sensi-
tive to small changes in bronchoconstriction [2] and
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hence more suitable for studies in normal subjects, in
whom the response to bronchoconstrictors is, limited [3].
The interrupter method has been shown to be a simple
and non-invasive technique of measuring airway mechan-
ics in children or patients with limited co-operation [4]. It
is also suitable for diagnostic purposes in the detection
and exclusion of asthma [5] and in obtaining valid rhi-
nomanometric measurements in various groups of
patients [6].
An official statement by the ATS (American Thoracic Soci-
ety) on methacholine provocation indicated that the
interrupter method may be useful in testing patients who
cannot perform acceptable spirometry manoeuvres but its
use should be restricted to laboratories with expertise in
their application and interpretation [7]. Furthermore,
concerns have been raised about pressure equilibration
during flow interruption [8] and when small increases in
resistance are used as provocation thresholds, the repeat-
ability of the method was found unacceptably low and
unsuited for clinical and research purposes [9]. In addi-
tion, the studies performed so far with this technique were
done on too small numbers of subjects to allow firm sci-
entific conclusions.
We hypothesized that, since normals present with lower
levels of airway obstruction during challenge, the inter-
rupter technique in this case might be suitable and com-
parable with the reference PD20FEV1  method, and
therefore clinically useful.
Methods
Subjects
The study was conducted in a tertiary referral centre for
respiratory disease and 198 subjects were initially
enrolled. All subjects were healthy with a negative history
and physical examination, normal blood counts, chemis-
tries, chest radiography and spirometry.
One individual from this sample reacted to the diluent
control solution (0.6%), defined as a resistance difference
of > 30% baseline [9] and was excluded together with non
evaluable data from 27 subjects. The final data of 170 nor-
mals were finally included, consisting of 100 (59%) males
and 70 (41%) females. Predicted values for spirometry
were obtained according to the European Community
Coal and Steel (ECCS) [10]. All participants were given
detailed information of the purpose of the study, which
was approved by the hospital ethics committee, and
signed a consent form. They were asked to come in the
next morning, avoiding all factors listed in the ATS guide-
lines [7] that might cause a false negative test.
Methods
Routine spirometry was performed according to standard-
ized guidelines [11]. Interrupter resistance was measured
at end interruption (Rint, EI) using the technique by Pha-
goo et al.[12], who showed that the Rint, EI reflected
changes in lung mechanics more sensitively, than inter-
rupter resistance measured at mid or begining of interrup-
tion. The Rint, EI is calculated from the airway opening
pressure (time function) signal airway opening pressure
Pao(t) as follows: based on the assumption that, during a
brief (100 ms) airflow interruption there is equilibration
between alveolar pressure (PA) and Pao, the Rint, EI is
obtained by dividing the change in pressure by the imme-
diately preceding flow. In this study we used the alterna-
tive method of opening the interrupter [13], which
calculates Rint, EI from the Pao signal using a calibration
resistance.
The airflow interruptions were performed using the Bron-
choscreen system (Jaeger, Würzburg, Germany) [8], a
computerized apparatus with a combined nebulizer-shut-
ter head, which allows the changes in resistance of the res-
piratory system Rint, EI) to be measured with each breath.
During quiet breathing, the opening interrupter Rint, EI
was calculated. The seated subject (with noseclip in place
and the cheeks partly supported by a rubber mouthpiece)
breathed in a relaxed manner (in order to avoid glottic
artifacts) ambient air to get accustomed to the apparatus.
The shutter closed within 15 ms. The time of complete air-
flow interruption was 100 ms. It was triggered 150 ms
after the onset of expiration. The dead space of the appa-
ratus was 0.35 L. The pressure transducer (Honeywell 142
PC 01G; Chesham, Bucks, UK) was connected via a side
port directly to the mouthpiece at a distance of 18 cm
from the airway opening. Rint, EI was calculated by the
formula: Rint, EI = (PA/Pm) × Rref, where PA is the end
interruption mouth pressure, Pm the pressure generated
during free flow and Rref is a fixed serial resistance. The
triggering volume was determined by integrating the sig-
nal from a low resistance Lilly Pneumotach, which had a
linearity of ± 2% at a flow below 12 L/s. Before each chal-
lenge the interrupter was calibrated. A vent produced an
airflow of 105 L/min, which was led through the shutter
and a calibrating resistance (0.10 kPa/L/s) and the deter-
mined Rint,EI had to be within ± 10% of the reference
resistance. The above method has been found valid in the
presence of mild to moderate bronchoconstriction [14],
conditions that are normally met during bronchial
challenge.
Bronchial responsiveness was measured by a rapid meth-
acholine provocation dosimetric test, as previously
described by our group with the same apparatus but using
histamine instead [15]. Briefly, 1% methacholine in saline
(Lofarma, Italy) was inhaled in doubling doses startingBMC Pulmonary Medicine 2004, 4:11 http://www.biomedcentral.com/1471-2466/4/11
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from 200 µg, until FEV1 had fallen = 20% compared with
FEV1 after an initial saline inhalation. The bronchial aero-
sol provocation system (APS Jaeger, Wurzburg, Germany)
was used in this procedure. The nebulizer was calibrated
to draw 5 µL of solution per automatic actuation lasting
0.6 seconds. The 100 µL of aerosol bolus had a mass
median aerodynamic diameter of 1.9 µm with 80% of the
droplets being less than 5.5 µm at a set pressure of 1.6 bar
(22.8 psi). The subjects inhaled methacholine by slow
inspiratory capacity manoeuvres guided by the green col-
our of light emission diodes (so that inspiratory flow was
<0.5l/s) and the response was assessed 1 min after each
inhaled dose.
Data was assessed by using two different estimates: 1)
provocation dose which increases Rint, EI by 100%
(PD100Rint, EI), calculated by interpolation from the last
two points of the cumulative semilogarithmic dose-
response diagram, and 2) the percent slope (dose-
response ratio-DRR) of a line extending from the origin to
the last point of the curve (DRR) [16]. Plateau response
was defined as difference in Rint, EI <40% after the deliv-
ery of three consecutive doubling doses and/or DRR<40%
after a total cumulative dose of 4 mg or a PD100 Rint, EI >4
mg. The DRR data were analyzed from the whole sample.
The 10 day reproducibility of the PD100Rint, EI was inves-
tigated by randomly asking 39 subjects to come again after
one week for a second examination. During the second
visit we compared Rint, EI with FEV1 as measurements of
response to provocation, the latter determined 30 s after
the assessment of Rint, EI [9,17]. At least two technically
correct forced expiratory manoeuvres with an FEV1 varia-
tion within ± 5% were received and the highest value was
used for calculating the dose producing a 20% fall in FEV1
(PD20FEV1).
Statistical analysis
Regression analysis and correlation, Shapiro-Wilk test for
normality and the non-parametric Mann-Whitney-U-/
Wilcoxon Rank Sum test with normal approximation and
the x2 test, were used for statistical analysis. The relative
duplicate error was used to assess test-retest reproducibil-
ity of the PD100Rint, EI (assuming a normal distribution),
defined as a standard deviation of the differences divided
by the v2 after log transformation (approximates coeffi-
cient of variation)[18]. Agreement between PD100Rint, EI
and PD20FEV1 was defined and calculated according to
Bland and Altman [19]. Normal bronchial responsiveness
was defined at a cut-off level of > 0.8 mg methacholine
[20], while negative non-response reactions were those >
2.0 mg (8.8 µmoL)[21].
Results
Subjects' anthropometric data and baseline spirometry are
shown in Table 1. Mean values of vital capacity (VC), FEV1
and maximal expiratory flow when 50% of the forced vital
capacity (FVC) remains to be exhaled (Vmax50), were
higher in males by 16.3%, 14, 7% and 2.5% than in
females. While Rint, EI was higher in females, possibly
reflecting smaller airway size, but these differences were
not statistically significant. The distribution of PD100Rint,
EI is shown in Figure 1.
Twenty one males and ten females (18%) of our subjects
exhibited bronchial hyperesponsiveness. These values
were normally distributed (W = 0.93, p = 0.12), with no
gender related difference (x2 = 1.48, p = 0.22, odds =
1.79). Furthermore, 5 of these 31 subjects (3 men and 2
women, 3% of total) were found to show moderate bron-
chial hyperesponsiveness (PD100Rint, EI < 0.4 mg or <
Analysis of the distribution of PD100Rint, EI (threshold dose)  in males and females Figure 1
Analysis of the distribution of PD100Rint, EI (threshold dose) 
in males and females. Values >4 mg are derived by 
extrapolation.
Table 1: Characteristics of the study population stratified by 
gender.
Variables Men Women
n = 100 n = 70
Age, mean (range) yr 38 (18–60) 35 (18–55)
Height, mean (cm), SEM 174 (0.78) 160 (0.71)
Weight, mean (kg), SEM 79 (0.9) 63 (0.9)
Rint, EI, mean (kPa/l/s), SEM 0.24 (0.069) 0.29 (0.074)
VCin, mean (%pred), (range) 111.5 (83–144) 95.2 (76–129)
FEV1, mean(%pred), (range) 107.9 (75–125) 93.2 (78–110)
FEV1 % mean (range) 83 (77–92) 82 (75–90)
Vmax50, mean (%pred), (range) 83.5 (70–155) 81 (65–145)
Abbreviations: VC in: inspiratory vital capacity, FEV1: forced 
expiratory volume in 1 sec, FEV1%: ratio of forced expiratory volume 
in 1 sec to forced vital capacity, Vmax50: maximum flow at 50% of 
forced vital capacity, Rint, EI:Interrupter Resistance at End 
InterruptionBMC Pulmonary Medicine 2004, 4:11 http://www.biomedcentral.com/1471-2466/4/11
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1.66 µmol methacholine), as frequently found in current
symptomatic asthmatics [21]. No correlation was found
of PD100Rint, EI to baseline post-saline Rint, EI and the
respective DRR. Subjects with negative reactions (> 8.8
µmol) showed DRRs that were ten times lesser compared
to those with BHR (mean ± SD = 67.52 ± 10.66 vs 690 ±
390, p < 0.001). Plateau response was exhibited by 66
(38%) of the subjects, (36 males) without gender related
statistical difference (x2 = 0.81, p= 0.36). They had DRRs
that were 2.5 times smaller compared to the subjects with
normal but measurable reactions (30.1 ± 9.8 vs. 75.0 ±
49.9, p = 0.024).
PD100Rint, EI was found reproducible with a duplicate
error of 8.3% or 0.65 doubling doses (within 140 µg). A
close correlation was found between PD100Rint, EI and
PD20FEV1 (r = 0.76, 95% CI 0.53-0.88) with relatively nar-
row limits of agreement (Figure 2.) Stratification of data
according to BHR status is shown in Table 2. The inter-
rupter method showed DRRs that were more reactive in
comparison to the respective DRRs of FEV1(approxi-
mately seven-fold).
Discussion
In this study we have shown that the interrupter tech-
nique, and specifically PD100Rint, EI, is comparable to the
conventional PD20FEV1 method for evaluation of BHR in
a large sample of normal subjects. We have also found
that this technique has a specificity of 81.2% for normal
subjects and its dose response ratio is 7-fold more sensi-
tive than the conventional FEV1 method. It is known that
specific airway conductance is four times more sensitive
than FEV1 as a measure of response to provocation but the
use of a body plethysmograph makes assessment of bron-
chial challenge expensive and time consuming. The
present methodology is particularly useful in children and
in the elderly, since it is non-invasive, sensitive to changes
in airway calibre and requires no subject co-operation.
The opening interrupter technique offers the additional
advantage of simplicity and ease of application, being par-
ticularly useful in subjects unable to perform forced
manoeuvres.
The Rint, EI was measured during expiration above forced
residual capacity (FRC), because resistance hardly changes
above this level and since subjects performed relaxed tidal
flow maoeuvres, measurements were not affected by vari-
ations in breathing. Furthermore, we did not correct Rint,
EI by lung volumes because the variability formed in the
FRC can reduce the benefit of standardization of Rint, EI
and the correlation between respiratory resistance and
FRC is not significant over the limited FRC range of
healthy subjects [21]. Problems in repeatability have been
reported when one uses provocative concentration caus-
ing a 30% increase in Rint, EI (PC30Rint, EI), so we
assessed the PD100Rint, EI threshold, which is above the
95 % confidence interval at one tail direction (1.96SD)
observed in our normal sample at baseline (Table 1). Fur-
thermore, although a correlation of the PC40Rint, EI with
the classical provocative concentration causing a 20% fall
in FEV1 (PC20FEV1) has been reported (17), data on agree-
ment are presented for the first time in this study.
If a cut-off value is set at 0,4 mg PD100Rint, EI metha-
choline, which defines severe and moderate hyperrespon-
siveness compatible with asthma [22] then 3% of the
studied normal population was found to be in this area.
This is similar to the percentage found by Malo et al. [23]
working with PC20FEV1 as well as to 2.5%, which repre-
sents the proportion of subjects beyond the 2 SD of the
mean on one side of a normal distribution. If the
PD100Rint, EI threshold is set at 0,8 mg methacholine
[18], which includes mild BHR, then 18% of the total sub-
jects studied had some degree of hypersensitivity. Contra-
dictory results have been previously reported regarding
the clinical significance of asymptomatic BHR. Some stud-
ies, using even stricter definitions of BHR, showed that
asymptomatic BHR is of no significance [24]. In contrast
other studies have reported an increased rate of decline of
lung function in an asymptomatic population with BHR
[25]. A plateau with a low maximal response was exhib-
ited by 38% of the subjects, thus representing the least
reactive part of the sample. Seppala et al.[26], using a
method incorporating a deep inhalation (FEV1) showed
that 50% of normals had no calculable PC20FEV1.
Bland and Altman plot of the differences between two meth- ods against their mean value Figure 2
Bland and Altman plot of the differences between two meth-
ods against their mean value. The limits of agreement (  -2s 
and   +2s) are -0.334 mg (-1.39 µmol) and 0.306 mg (1.27 
µmol) respectively. The 95% confidence intervals are -0.364 
to -0.303 mg and 0.275 to 0.336 mg, respectively.
d
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In this study, by direct comparison of two methods, one
involving a deep inhalation, the relative effects of maxi-
mal expiratory manoeuvres on airway calibre can be indi-
rectly assessed. The data in Table 2 show that while
threshold doses between the two methods are essentially
similar and not statistically significant, there is a signifi-
cant difference in the DRRs between the two methods,
being more pronounced in normal subjects showing BHR.
Recently, Sundblad et al [27] reported a significant corre-
lation between dose response slopes of FEV1 and airway
conductance in a large sample of subjects but not all were
normals. It is known that in bronchial challenge the dose-
response curve is expressed mainly by the threshold dose
indicating hyperresponsiveness and the rate and magni-
tude of the response (hyperreactivity, DRR). The less reac-
tive DRRs of the FEV1  method lend support to the
perturbed actomyosin equilibrium hypothesis recently
described, in that with stretching there is a decrease in
myosin duty cycle and the magnitude of the contractile
response becomes functionally disengaged from the level
of the contractile stimulus [28]. Furthemore, since there is
indirect evidence of a lack of airway inflammation or
remodelling that could prevent smooth muscle from
stretching, our data are in agreement with those of Kol-
naar et al. [24]. The fact that airway elastic recoil decreases
(increase in hysteresis) when smooth muscle is contracted
[1], explains the greater difference in DRRs exhibited by
subjects showing BHR (the prevailing distending force of
the lung allows the airway to dilate more after deep
inhalation).
No correlation was found in this study between BHR and
baseline airway calibre, although Malo et al.[23] found a
weak correlation by using a more sensitive parameter i.e.
the PC6 FEV1. The limits of agreement between PD100Rint,
EI and the classical PD20FEV1 were found relatively small
at -1.39 µmol and 1.27 µmol respectively. This implies
that this method may be used as an alternative to FEV1
during provocation, as it is simple and easy to perform
and requires no patient co-operation.
Gender differences in BHR were explored because of the
smaller lung size in women. Our data are in agreement
with recent studies [29] that in non smoking women, lung
size has no effect on bronchial sensitivity. Since RintL was
found more sensitive than RintEI, a study comparing the
two methods with the classical method would be interest-
ing [30].
Conclusions
In summary, the interrupter technique as an index of
response to provocation has been shown to be useful to
assess bronchial responsiveness in normal subjects, when
maximal efforts cannot be performed. We recommend
threshold doses of 100% baseline, because they show reli-
able agreement with the classical PD20FEV1 method.
List of abbreviations
ATS:American Thoracic Society, BHR:Bronchial Hyperre-
sponsiveness, DRR:Dose Response Ratio, FEV1:Forced
Expiratory Volume in 1 sec, FVC:Forced Vital Capacity,
FRC:Functional Residual Capacity, PA:Alveolar Pressure,
Pao: airway opening Pressure, PC20FEV1:Provocative Con-
centration causing a 20% fall in FEV1, PC30Rint, EI:Pro-
vocative Concentration causing a 30% increase in Rint, EI,
PD100Rint, EI: Provocation dose which increases Rint, EI
by 100%, PD20FEV1:Provocation Dose producing a 20%
Table 2: Comparison of the methods described in the text in terms of threshold dose (sensitivity) and dose-response ratio (reactivity), 
stratified according to BHR status. NS: p value not statistically significance between the two methods. The greater reactivity of the 
interrupter method is shown.
Methods (× ± SD)
Subjects showing BHR
PD100Rint, EI (mgs) 0.57 ± 0.20 Dose-response ratio (%/mg) 690 ± 390
PD20FEV1 (mgs) 0.72 ± 0.66 Dose-response ratio (%mg) 98 ± 90
NS P < 0.05
Subjects with normal 
measurable reactions (> 0.8 
mgs)
PD100Rint, EI (mgs) 3.42 ± 3.10 Dose-response ratio (%/mg) 74.86 ± 49.87
PD20FEV1 (mgs) 3.13 ± 2.65 Dose-response ratio (%/mg) 20 ± 3.82
NS P < 0.05
Abbreviations: BHR :Bronchial Hyperresponsiveness, Rint, EI:Interrupter Resistance at End Interruption, PD20FEV1:Dose Producing a 20% fall in 
FEV1.BMC Pulmonary Medicine 2004, 4:11 http://www.biomedcentral.com/1471-2466/4/11
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fall in FEV1, Rint, EI:Interrupter Resistance at End Inter-
ruption, VC:Vital Capacity,
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